Comparative Pharmacology
Head-to-head clinical analysis: BROMDAY versus OMIDRIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMDAY versus OMIDRIA.
BROMDAY vs OMIDRIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby suppressing histamine-mediated allergic and vasodilatory responses.
OMIDRIA is a fixed-dose combination of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist that causes vasoconstriction.
1-2 drops in each affected eye every 4-6 hours as needed, not to exceed 4 doses per day.
1 mL of the fixed-dose combination (ketorolac 0.45% / phenylephrine 1%) administered intracamerally as a single dose at the time of cataract surgery.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in hepatic impairment.
Ketorolac: terminal half-life of 5.3 hours (range 3.8-8.2 hours) in adults; phenylephrine: terminal half-life of 2-3 hours. Clinically, ketorolac's half-life supports twice-daily dosing.
Renal excretion (approximately 70%) as unchanged drug and metabolites; biliary/fecal excretion accounts for the remainder.
Renal elimination of ketorolac accounts for approximately 91% of the dose, with approximately 60% as unchanged drug and the remainder as metabolites; phenylephrine is primarily metabolized and excreted in urine as sulfate conjugates, with <20% excreted unchanged.
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID and Mydriatic Combination